Cellular Immunology of Myocarditis: Lights and Shades-A Literature Review

Cells. 2024 Dec 17;13(24):2082. doi: 10.3390/cells13242082.

Abstract

Myocarditis is an inflammatory disease of the myocardium with heterogeneous etiology, clinical presentation, and prognosis; when it is associated with myocardial dysfunction, this identifies the entity of inflammatory cardiomyopathy. In the last few decades, the relevance of the immune system in myocarditis onset and progression has become evident, thus having crucial clinical relevance in terms of treatment and prognostic stratification. In fact, the advances in cardiac immunology have led to a better characterization of the cellular subtypes involved in the pathogenesis of inflammatory cardiomyopathy, whether the etiology is infectious or autoimmune/immune-mediated. The difference in the clinical course between spontaneous recovery to acute, subacute, or chronic progression to end-stage heart failure may be explained not only by classical prognostic markers but also through immune-pathological mechanisms at a cellular level. Nevertheless, much still needs to be clarified in terms of immune characterization and molecular mechanisms especially in biopsy-proven myocarditis. The aims of this review are to (1) describe inflammatory cardiomyopathy etiology, especially immune-mediated/autoimmune forms, (2) analyze recent findings on the role of different immune cells subtypes in myocarditis, (3) illustrate the potential clinical relevance of such findings, and (4) highlight the need of further studies in pivotal areas of myocarditis cellular immunology.

Keywords: autoimmune disease; immune system; immunosuppressive therapy; myocarditis; systemic immune-mediated disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Myocarditis* / immunology
  • Myocarditis* / pathology
  • Myocardium / immunology
  • Myocardium / pathology

Grants and funding

A.L.P.C. acknowledges the support of Budget Integrato per la Ricerca dei Dipartimenti (BIRD, year 2019), Padua University, Padua, Italy (project title: Myocarditis: genetic background, predictors of dismal prognosis and of response to immunosuppressive therapy); of the Italian Ministry of Health, Target Research, Rome, Italy, year 2019, RF-2019-12370183 (project title: Biopsy-proven myocarditis: genetic background, predictors of dismal prognosis and of response to immunosuppressive therapy and preclinical evaluation of innovative immunomodulatory therapies); and by the European Union—Next Generation EU—NRRP M6C2—Investment: 2.1 “Enhancement and strengthening of biomedical research in the NHS” (project title: Biopsy-proven pediatric and adult giant cell and other rare immune-mediated forms of myocarditis: creation of a prospective multicenter Italian registry and a biobank network to identify clinical, immune, and genetic predictors of dismal prognosis, relapse, and response to immunosuppressive therapy; code PNRR-MR1-2022-12375693, Cup: I93C22000560006). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union.